By Keith Loria
Executive Overview
For decades, a diagnosis of feline infectious peritonitis (FIP) was among the most devastating verdicts a veterinarian could deliver. Caused by a mutation of the ubiquitous feline coronavirus, the disease was historically regarded as uniformly fatal, leaving clinicians with little to offer beyond palliative care and compassionate discussions about euthanasia.
Today, the landscape of veterinary medicine has fundamentally transformed. The advent of targeted antiviral medications has turned FIP from an inevitable death sentence into a manageable, and frequently curable, condition. However, this therapeutic revolution has exposed a critical vulnerability in modern veterinary practice: the lack of a single, highly dependable antemortem diagnostic test that can definitively confirm or rule out the disease in every patient.
To bridge this dangerous diagnostic gap, a team of veterinary researchers has evaluated an innovative diagnostic technique known as multiplex fluorescent immunocytochemistry (MF-ICC). Published in a recent diagnostic study, the assay detects feline coronavirus antigens specifically within macrophages—the primary target cells of systemic FIP—without requiring invasive surgical biopsies.
While researchers emphasize that MF-ICC is not a standalone "silver bullet," its integration into current diagnostic workflows promises to drastically improve the speed and accuracy of FIP detection. As effective antivirals raise the stakes of accurate diagnosis, this new tool marks a significant step forward in veterinary internal medicine.
Detailed Chronology: The Evolution of FIP Diagnostics
To understand the significance of the MF-ICC assay, one must examine the historical trajectory of FIP diagnosis and the persistent hurdles clinicians face.
The Diagnostic Challenge of the Noneffusive Form
FIP primarily manifests in two forms: effusive ("wet"), characterized by fluid accumulation in the abdomen or chest, and noneffusive ("dry"), characterized by granulomatous lesions in organs such as the kidneys, liver, eyes, and central nervous system.
While effusive FIP can sometimes be diagnosed via analysis of characteristic abdominal or chest fluid, the noneffusive form has remained notoriously elusive.
"FIP is extremely diagnostically challenging, primarily in the noneffusive form," explains Samantha J.M. Evans, DVM, PhD, DACVP, DACVM, associate professor of clinical pathology at Colorado State University (CSU) and lead author of the new diagnostic study. "It’s much more important now to get a diagnosis, because we actually have treatment available."
Limitations of Legacy Testing
Historically, clinicians have relied on a patchwork of tests, none of which provide absolute certainty on their own:
- Reverse Transcription-Polymerase Chain Reaction (RT-PCR): Detects viral RNA, but cannot reliably differentiate between benign enteric coronavirus infections and systemic FIP.
- Serology: Measures the cat’s antibody response to the coronavirus. Because feline coronavirus is widespread—especially in multi-cat environments—high antibody titers often indicate mere exposure rather than active, clinical FIP.
- Serum Albumin-to-Globulin (A:G) Ratio: A low A:G ratio provides biochemical suspicion, but lacks specificity.
- Histopathology and Immunohistochemistry (IHC): Considered the historical gold standard, this requires examining tissue samples under a microscope. However, obtaining these samples often necessitates invasive surgical procedures on patients that are already critically ill and unstable.
The Innovation of MF-ICC
Recognizing these limitations, Dr. Evans and her collaborators turned to multiplex fluorescent immunocytochemistry. Rather than searching broadly for viral RNA or antibodies, MF-ICC targets the virus inside the specific cellular vehicle responsible for spreading the disease.
The assay utilizes fluorescent antibodies to simultaneously detect two markers:
- Feline coronavirus antigen (the pathogen).
- Vimentin (a cellular marker that identifies macrophages, the hallmark immune cells central to systemic FIP pathology).
By using advanced imaging to superimpose wavelengths, technicians can confirm whether the viral antigen is present directly inside macrophage-like cells.
"The innovation we added was multiplexing [the viral marker] with another marker for cellular antigen called vimentin," Dr. Evans explains. "That cellular marker allows us to look specifically at macrophages, which are the hallmark cell type of FIP."
Co-author Benjamin Curtis, DVM, DACVP, a clinical assistant professor at the University of Michigan’s Unit for Laboratory Animal Medicine Pathology Core, highlights the practical advantages of the methodology:
"It’s minimally invasive," Dr. Curtis says. "Pulling fluid out of the belly or doing a needle aspirate is much less invasive than needing to do a tissue biopsy. But then it brings in the gold-standard concept of immunohistochemistry, in that we can confirm there is viral antigen inside the cells that matches the presentation of FIP."
Supporting Context & Metrics: Evaluating the Clinical Trial
To rigorously test the efficacy of MF-ICC, the research team conducted a clinical trial involving 84 feline patients: 58 diagnosed with confirmed FIP and 26 control cases suffering from other illnesses.
The investigators directly compared the performance of MF-ICC against three established diagnostic benchmarks: RT-PCR, serology, and the serum albumin-to-globulin ratio. Final case determinations were established using necropsy findings with histopathology, immunohistochemistry, documented response to antiviral treatment, and comprehensive clinical follow-up.
Key Performance Metrics
Using a diagnostic threshold of at least one cell positive for both coronavirus antigen and vimentin, the MF-ICC assay yielded striking results:
- Sensitivity: 77 percent
- Specificity: 81 percent
- Positive Predictive Value (PPV): 92 percent
- Negative Predictive Value (NPV): 53 percent
- Overall Accuracy: 78 percent
For comparison within the same patient cohort, overall diagnostic accuracy stood at 76 percent for the serum albumin-to-globulin ratio, 75 percent for serology, and 69 percent for RT-PCR.
Surprising Findings from the Data
One of the most unexpected outcomes of the study challenged conventional assumptions regarding viral load thresholds. Dr. Evans noted that researchers were surprised to find that the presence of a single dual-positive cell was sufficient to achieve peak diagnostic accuracy.
"Literally a single virus-infected cell was enough information to discriminate FIP versus non-FIP disease," she notes. "It was surprising to me that little material was clinically significant."
Furthermore, performance metrics varied depending on the sample type and disease phenotype. MF-ICC proved more sensitive—though slightly less specific—when performed on effusion fluids. Conversely, in tissue samples derived from cats with the notoriously difficult noneffusive form of the disease, a positive MF-ICC result carried exceptionally strong diagnostic weight.
Importantly, the researchers emphasize that MF-ICC does not render PCR or other methods obsolete. The assays frequently identified different subsets of positive patients.
"MF-ICC picked up some FIP cases that PCR did not, and PCR picked up some FIP cases that MF-ICC did not," Dr. Evans explains. "There is value to ordering both. You’ll have a greater chance of picking up an FIP case by submitting both, and the same sample type can be used for these different assays in a complementary way."
While a positive MF-ICC result is a powerful indicator of FIP, a negative result cannot categorically rule out the disease. Anatomical factors—such as localized viral concentrations in the central nervous system or ocular tissues—mean that clinicians must always interpret laboratory data alongside the broader clinical picture.
Official Statements: The Clinical Impact on Veterinary Practice
The stakes for accurate, rapid diagnosis have never been higher. In the pre-antiviral era, an uncertain diagnosis often prompted immediate discussions regarding palliative care or euthanasia. Today, diagnostic uncertainty carries entirely different risks: it can delay life-saving therapy, subject pet owners to costly and prolonged treatments for the wrong disease, or mask underlying comorbidities.
Dr. Curtis underscores the profound time constraints clinicians face when treating severely compromised felines:
"Having something with a rapid turnaround is going to be life and death for a lot of cats," he says. "Being able to get a rapid answer lets owners and veterinarians know whether we need to start moving on treatment or make other decisions."
This sentiment is echoed by study co-author Petra Černá, PhD, DACVIM (SAIM), Dipl. ECVIM-CA, DABVP (Feline), MANZCVS, an assistant professor of small animal internal medicine at the University of Georgia. Dr. Černá has frequently witnessed the unintended consequences of empirical treatment without a confirmed diagnosis.
"It is very important to have access to fast and accurate diagnostic tests so we can confidently treat these cats," Dr. Černá states. "Very often, I see cases that have been treated for several weeks with antiviral therapy, and they do not have FIP. That is not good antiviral stewardship, but we are also missing the actual diagnosis and are not able to help these patients."
For general practitioners confronting ambiguous cases—such as when cytology samples have already been drawn, no material was retained for PCR, or PCR yields a negative result despite persistent clinical indicators—MF-ICC provides a vital safety net.
"I think this test is another helpful tool in our toolbox to feel more confident about FIP diagnosis," Dr. Černá adds. "No single test is perfect, and the more possibilities we have, the better we can diagnose these cats and treat them appropriately."
Future Outlook: Transitioning from Laboratory to Clinical Ecosystem
While MF-ICC represents a major methodological leap, it is not currently an in-clinic, point-of-care test. The procedure demands specialized laboratory equipment to concentrate cells onto slides, specific fluorescent reagents, and the expert eye of a veterinary pathologist to interpret staining patterns.
Expanding Access and Integration
To make this technology widely available, Colorado State University intends to offer the assay through its Veterinary Diagnostic Laboratory, continuously evaluating its performance as field data accumulates.
Dr. Evans envisions MF-ICC functioning not as an isolated assay, but as a cornerstone of a comprehensive FIP diagnostic service. This service will package MF-ICC alongside PCR, biochemical ratios, and patient metadata. Additionally, her research team is actively developing machine-learning tools driven by routine Complete Blood Count (CBC) and serum biochemistry findings. Meanwhile, CSU’s established FIP biobank and digital repository will facilitate ongoing retrospective evaluations.
Significantly, the underlying methodology is not proprietary. Dr. Curtis points out that any veterinary diagnostic laboratory equipped with the necessary hardware and expertise can acquire the required antibodies and reagents to establish the assay in-house, potentially reducing shipping delays and accelerating turnaround times nationwide.
The Road Ahead: Emerging Research Questions
As diagnostic accuracy improves, veterinary researchers are shifting their focus toward the complex medical challenges facing the growing population of FIP survivors. Dr. Černá stresses that future investigations must address patients that fail to respond predictably to standard antiviral protocols:
- Comorbidities: Managing critically ill patients suffering from severe systemic inflammation, suspected viral sepsis, immune-mediated hemolytic anemia, myocarditis, or concurrent infections.
- Long-Term Sequelae: Monitoring recovered patients who subsequently develop secondary gastrointestinal disorders or, in documented cases, large-scale medical conditions such as large-cell lymphoma—health phenomena that went unobserved in the past when FIP survival was virtually nonexistent.
Conclusion
Ultimately, the emergence of MF-ICC reaffirms a fundamental truth of modern veterinary medicine: conquering a complex disease requires abandoning the search for a single, magical test in favor of an integrated, evidence-based strategy.
"There’s no perfect test for FIP," Dr. Evans concludes. "One piece is PCR, one is MF-ICC, and this new test is one part of putting together that puzzle."
About the Author
A graduate of the University of Miami, Keith Loria is a D.C.-based, award-winning journalist who has been writing for major publications for close to 20 years on topics as diverse as veterinary medicine, travel, and entertainment. Loria started his career with the Associated Press and has held senior editorial positions at publications focused on healthcare, sports, and technology.
